Respiratory News and Research

RSS

Commentary on severe allergic reaction to mRNA SARS-CoV-2 vaccines

A commentary by John M. Kelso, Division of Allergy, Asthma and Immunology, Scripps Clinic, published in the latest issue of the journal Vaccines, discusses anaphylactic reactions to these novel mRNA SARS-CoV-2/COVID-19 vaccines.

8 Feb 2021

SARS-CoV-2 delays interferon signaling in host cells

A team of scientists from Sweden and India has recently conducted a study to evaluate type I interferon (IFN-I) responses in cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The findings reveal that SARS-CoV-2 infection is associated with a delayed and dysregulated IFN-I response and that pretreatment with IFN-I can reduce the risk of SARS-CoV-2 infection.

7 Feb 2021

Visualization of SARS-CoV-2 RNA by fluorescence in situ hybridization probes

A team of scientists from France has recently designed fluorescence in situ hybridization probes (CoronaFISH) to visualize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in infected cells. A detailed description of the probe design, validation, and application is currently available on the bioRxiv preprint server.

7 Feb 2021

Molecular surveillance of SARS-CoV-2 spike protein mutations using CovRadar

In a recent bioRxiv preprint research paper, scientists from Germany discuss how they made sequence information more easily accessible for epidemiologists and virologists.

7 Feb 2021

Subdominant SARS-CoV-2 epitopes key to understanding emerging variants

Researchers in the UK have conducted a study showing the importance of considering subdominant epitopes within severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) when investigating neutralizing antibodies that target the virus.

7 Feb 2021

Orthodox Jewish in UK disproportionately impacted by COVID-19

Researchers have conducted a study showing an extremely high prevalence of severe acute respiratory coronavirus disease 2 (SARS-CoV-2) within a strictly Orthodox Jewish community in the UK.

7 Feb 2021

Sleep studies could affect treatment decisions in children with sleep disordered breathing

A new study recommends healthy children with symptoms of sleep disordered breathing, such as snoring or temporary cessation of breathing, should consider undergoing a sleep study (polysomnography) and should discuss the potential benefits of this with their pediatrician or otolaryngologist to possibly manage the child's symptoms medically and before surgery.

6 Feb 2021

Researchers develop systems to detect an atypical fungus responsible for severe pneumonia

The group led by Dr. Enrique J. Calderón - "Clinical Epidemiology and Vascular Risk" at the Institute of Biomedicine of Seville - IBiS/University Hospitals Virgen del Rocío and Macarena/CSIC/University of Seville, also a member of CIBERESP, participated in a project with researchers from CIBER-BBN, in which they developed systems to detect Pneumocystis jirovecii, an atypical fungus responsible for very severe pneumonia in immunosuppressed patients.

6 Feb 2021

FDA permits marketing of new prescription only device to reduce snoring and mild sleep apnea

Today, the U.S. Food and Drug Administration authorized marketing of a new prescription only device intended to reduce snoring and mild obstructive sleep apnea.

5 Feb 2021

How does SARS-CoV-2 infect the pancreas?

To understand how SARS-CoV-2 infects the pancreas and investigate its effects, a team of researchers used the human iPSC (induced pluripotent stem cells)-derived pancreatic cultures and analyzed the post-infection cellular and molecular changes.

5 Feb 2021

AI model aids early detection of severe COVID-19 infection in children

Children have been less impacted by COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) than adults. But some children diagnosed with SARS-CoV-2 have experienced severe illnesses, including Multisystem Inflammatory Syndrome (MIS-C) and respiratory failure; nearly 80% of children with MIS-C become critically ill with a 2 to 4% mortality rate.

5 Feb 2021

Natural reinfection with respiratory syncytial virus varies based on antibody response

Researchers at Baylor College of Medicine found that while most individuals responded to respiratory syncytial virus (RSV) natural reinfection with a typical sustained antibody response associated with protection, a few individuals surprisingly responded atypically, not being able to sustain the antibody response, which declined to levels that made the individuals susceptible to RSV reinfection.

5 Feb 2021

Army scientists evaluate three nonhuman primate models of SARS-CoV-2 airborne infection

Army scientists evaluated three nonhuman primate species as potential models of SARS-CoV-2 airborne infection, according to results published online this week in PLOS ONE.

5 Feb 2021

Study indicates that 2019-2020 flu season was driven by a new, more transmissible strain

The 2019-2020 flu season in the U.S. was unusual in a number of ways. Cases picked up in August rather than the more typical fall and early winter months, and it hit children particularly hard. It was also dominated early on by a Type B influenza virus instead of one of the much more common Type A viruses like H1N1 or H3N2.

5 Feb 2021

Research shows intestinal parasite infestations reduce COVID-19 severity

Now, new research out of Mekelle, Ethiopia, examines the role of parasitic infestation on the prognosis of COVID-19. The research paper, which appears on the preprint server medRxiv, shows that intestinal parasitosis is protective against severe COVID-19.

4 Feb 2021

Greater muscle strength associated with lower risk of COVID-19 hospitalization

A new preprint research paper posted to the medRxiv* server discusses the results of a study exploring the relationship between increased muscle strength and hospitalization for severe COVID-19.

4 Feb 2021

Alpaca nanobodies neutralize SARS-CoV-2 in vitro

A new preprint research paper posted to the bioRxiv server reports the development of highly effective neutralizing nanobodies targeting the viral receptor-binding domain (RBD), thus disrupting its engagement with the host cell angiotensin-converting enzyme 2 (ACE2) receptor.

4 Feb 2021

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Among these is the B.1.1.7 SARS-CoV-2 variant, with its characteristic N501Y mutation. A new preprint on the bioRxiv server reports the impact of this mutation on CD4 T cell responses, including antigen presentation on cells expressing Major Histocompatibility Complex (MHC) class II molecules.

4 Feb 2021

COVID-19 vaccination alone may not end the pandemic

A simulation-based study conducted at the Miami University, USA, has revealed that vaccination of the general population against coronavirus disease 2019 (COVID-19) alone is not sufficient to control the pandemic, given the current availability and implementation strategies.

4 Feb 2021

ZyCoV-D SARS-CoV-2 DNA vaccine shows robust immunogenicity and protective efficacy in Rhesus macaquesys

A team of scientists from India has recently tested the efficacy and immunogenicity of two different concentrations of a plasmid DNA-based vaccine candidate ZyCoV-D. The findings reveal that the vaccine candidate administered via Needle Free Injection System (NFIS) can significantly induce the production of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG and neutralizing antibodies for a prolonged period.

4 Feb 2021